Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine and Bevacizumab in Metastatic Breast Cancer
NCT00468585Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jun 2005
- Primary completion
- Apr 2011
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of capecitabine in breast cancer, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Overall Objective Response Rate at 2 years. Started Jun 2005; status: completed.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00468585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00468585.